Acutus Medical, Inc. Just Filed Its Quarterly Report: Net Loss Per Common ...

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per common share excludes the potential impact of the Company’s convertible preferred stock, common stock options and warrants because their effect would be anti-dilutive due to the Company’s net loss. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same.
The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per common share because to do so would be anti-dilutive:
Six Months Ended June 30,
Shares issuable upon:20212020
(unaudited)
Conversion of Series A preferred stock— 391,210 
Conversion of Series B preferred stock— 3,088,444 
Conversion of Series C preferred stock— 4,499,921 
Conversion of Series D preferred stock— 8,593,360 
Exercise of stock options4,192,572 2,596,087 
Exercise of common stock warrants797,487 509,562 
Exercise of preferred stock warrants— 446,990 
Vesting of PSUs and RSUs907,320 — 
Total5,897,379 20,125,574 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Acutus Medical, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - June 24, 2022
Acutus Medical, Inc. director just disposed of 60,000 shares - June 3, 2022
Acutus Medical, Inc.'s Chief Financial Officer just picked up 100,000 shares - June 2, 2022

Auto Refresh

Feedback